Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2019 09:00 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International...
March 08, 2019 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates

SAN DIEGO, March 08, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018, and provided...
March 01, 2019 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31,...
February 12, 2019 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the...
January 28, 2019 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed...
December 05, 2018 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients - - Conference Call and Webcast Presentation at 8:30 a.m. ET Today - SAN DIEGO, Dec. ...
November 08, 2018 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting

SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral presentations and posters addressing clinical and preclinical...
November 01, 2018 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
October 25, 2018 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results

SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after...
October 02, 2018 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting

SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase...